Liver fibrosis: Pathophysiology, pathogenetic _targets and clinical issues
- PMID: 30213667
- DOI: 10.1016/j.mam.2018.09.002
Liver fibrosis: Pathophysiology, pathogenetic _targets and clinical issues
Abstract
The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic parenchymal injury, persistent activation of inflammatory response as well as sustained activation of liver fibrogenesis and wound healing response. Liver fibrogenesis, is a dynamic, highly integrated molecular, cellular and tissue process responsible for driving the excess accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) sustained by an eterogeneous population of hepatic myofibroblasts (MFs). The process of liver fibrogenesis recognizes a number of common and etiology-independent mechanisms and events but it is also significantly influenced by the specific etiology, as also reflected by peculiar morphological patterns of liver fibrosis development. In this review we will analyze the most relevant established and/or emerging pathophysiological issues underlying CLD progression with a focus on the role of critical hepatic cell populations, mechanisms and signaling pathways involved, as they represent potential therapeutic _targets, to finally analyze selected and relevant clinical issues.
Keywords: Hepatic myofibroblasts; Hepatic stellate cells; Liver biopsy; Liver fibrosis; Transient elestography.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis.Int J Mol Sci. 2019 Jun 1;20(11):2700. doi: 10.3390/ijms20112700. Int J Mol Sci. 2019. PMID: 31159366 Free PMC article. Review.
-
Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases.Histol Histopathol. 2015 Sep;30(9):1011-32. doi: 10.14670/HH-11-623. Epub 2015 Apr 21. Histol Histopathol. 2015. PMID: 25896393 Review.
-
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.Am J Physiol Cell Physiol. 2013 Oct 15;305(8):C789-99. doi: 10.1152/ajpcell.00230.2013. Epub 2013 Jul 31. Am J Physiol Cell Physiol. 2013. PMID: 23903700 Review.
-
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.Cells. 2019 Nov 11;8(11):1419. doi: 10.3390/cells8111419. Cells. 2019. PMID: 31718044 Free PMC article. Review.
-
Liver fibrogenesis: un update on established and emerging basic concepts.Arch Biochem Biophys. 2020 Aug 15;689:108445. doi: 10.1016/j.abb.2020.108445. Epub 2020 Jun 7. Arch Biochem Biophys. 2020. PMID: 32524998 Review.
Cited by
-
Liver Fibrosis is Associated with Clinical Outcomes in Patients with Intracerebral Hemorrhage.Neuropsychiatr Dis Treat. 2022 Sep 8;18:2021-2030. doi: 10.2147/NDT.S375532. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36105249 Free PMC article.
-
Unveiling the Impact of BMP9 in Liver Diseases: Insights into Pathogenesis and Therapeutic Potential.Biomolecules. 2024 Aug 15;14(8):1013. doi: 10.3390/biom14081013. Biomolecules. 2024. PMID: 39199400 Free PMC article. Review.
-
In Vitro Investigation of the Anti-Fibrotic Effects of 1-Phenyl-2-Pentanol, Identified from Moringa oleifera Lam., on Hepatic Stellate Cells.Int J Mol Sci. 2024 Aug 19;25(16):8995. doi: 10.3390/ijms25168995. Int J Mol Sci. 2024. PMID: 39201682 Free PMC article.
-
Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives.Acta Pharm Sin B. 2020 Jul;10(7):1279-1293. doi: 10.1016/j.apsb.2020.03.007. Epub 2020 Apr 21. Acta Pharm Sin B. 2020. PMID: 32874828 Free PMC article. Review.
-
Metabolomics reveals that chronic restraint stress alleviates carbon tetrachloride-induced hepatic fibrosis through the INSR/PI3K/AKT/AMPK pathway.J Mol Med (Berl). 2024 Jan;102(1):113-128. doi: 10.1007/s00109-023-02395-4. Epub 2023 Nov 23. J Mol Med (Berl). 2024. PMID: 37993562
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
